The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model

被引:44
作者
Caers, J
Günthert, U
De Raeve, H
Valckenborgh, EV
Menu, E
Van Riet, I
Van Camp, B
Vanderkerken, K
机构
[1] Vrijie Univ Brussel, Dept HEIM, B-1090 Brussels, Belgium
[2] Vrijie Univ Brussel, Dept Haematol & Immunol, B-1090 Brussels, Belgium
[3] Univ Basel, Inst Med Microbiol, Dept Clin & Biol Sci, Basel, Switzerland
[4] Univ Antwerp, Dept Pathol, Antwerp, Belgium
关键词
multiple myeloma; osteopontin; CD44; variants; survival; invasion;
D O I
10.1111/j.1365-2141.2005.05886.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma (MM) is a malignancy characterised by the accumulation of monoclonal plasma cells in the bone marrow. Different reports indicate the expression of CD44 variant isoforms (CD44v) by MM cells. Osteopontin (OPN), which is expressed by MM cells, is known to be a ligand for CD44v6. In this study, we investigated the role of OPN with emphasis on a functional correlation between OPN and CD44v in the 5T33MM model. Our group reported the expression of CD44v by 5T33MM cells. Using this model, we have demonstrated the secretion of OPN by 5T33MM cells. OPN affected 5T33MM cell survival by increasing proliferation and inhibiting apoptosis. OPN also stimulated 5T33MM cell migration, transendothelial migration and matrix metalloproteinase-9 activity. We confirmed the proliferative and migratory effects of OPN on human MM cells. By applying inhibiting anti-CD44v6 antibodies, we found that OPN stimulated cell proliferation by engaging this isoform. Anti-CD44v antibodies and RGD peptides both inhibited cell migration, suggesting an involvement of both, CD44v isoforms and integrins. In conclusion, OPN may act as a mediator of MM cell survival by engaging CD44v. The protein is further involved in migration and invasion of MM cells through the activation of either alpha v beta 3 integrin or CD44v isoforms.
引用
收藏
页码:469 / 477
页数:9
相关论文
共 39 条
[1]   Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion [J].
Abe, M ;
Hiura, K ;
Wilde, J ;
Shioyasono, A ;
Moriyama, K ;
Hashimoto, T ;
Kido, S ;
Oshima, T ;
Shibata, H ;
Ozaki, S ;
Inoue, D ;
Matsumoto, T .
BLOOD, 2004, 104 (08) :2484-2491
[2]   Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators [J].
Angelucci, A ;
Festuccia, C ;
D'Andrea, G ;
Teti, A ;
Bologna, M .
BIOLOGICAL CHEMISTRY, 2002, 383 (01) :229-234
[3]  
Asosingh K, 2001, CANCER RES, V61, P2862
[4]  
Asosingh K, 2000, CANCER RES, V60, P3096
[5]  
Asosingh K, 2005, HAEMATOLOGICA, V90, P810
[6]   Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor [J].
Broek, IV ;
Asosingh, K ;
Allegaert, V ;
Leleu, X ;
Facon, T ;
Vanderkerken, K ;
Van Camp, B ;
Van Riet, I .
LEUKEMIA, 2004, 18 (05) :976-982
[7]   The integrin αvβ3 and CD44 regulate the actions of osteopontin on osteoclast motility [J].
Chellaiah, MA ;
Hruska, KA .
CALCIFIED TISSUE INTERNATIONAL, 2003, 72 (03) :197-205
[8]   Role of osteopontin in cellular signaling and toxicant injury [J].
Denhardt, DT ;
Giachelli, CM ;
Rittling, SR .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :723-749
[9]   CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma [J].
Eisterer, W ;
Bechter, O ;
Hilbe, W ;
van Driel, M ;
Lockhorst, HM ;
Thaler, J ;
Bloem, AC ;
Günthert, U ;
Stauder, R .
LEUKEMIA RESEARCH, 2001, 25 (12) :1051-1057
[10]  
FISHER LW, 1987, J BIOL CHEM, V262, P9702